Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
Positive clinical results for Active Biotech's prostate cancer project TASQ
October 25th, 2006
An interim analysis of the ongoing TASQ Phase I study shows a treatment effect for all evaluated prostate cancer patients. Phase II/III studies are planned to start in year 2007. The Phase I study comprises a total of 24 patients with so called hormone refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of prostate specific antigen (PSA), which is a surrogate marker for tumor progression. The current interim analysis was made after 10 patients had passed four months of TASQ treatment. Treatment with 0.5 mg TASQ...
Source: Biotech Week (2006-10-25)
|
